PQQ

The VerdictLOW CONVICTIONVerdict Score 43Worth-It: Low ROI (43/100)

The supplement that activates the same cellular switch as exercise — and only the switch.

Skip the PQQ bottle. The biomarker rises exactly as the marketing predicts, and the only independent academic trial confirmed the performance, fitness, and body composition that biomarker is supposed to predict did not move at all.

PQQ is a small ring-shaped molecule first discovered in soil bacteria. People take it because in cell-culture experiments it flips the same master switch that aerobic exercise flips — the one that tells your cells to build new mitochondria. The catch is that flipping the switch in a Petri dish is not the same as building useful mitochondria in a working human, and when researchers ran the obvious test, the switch flipped and the performance did not.

That's the general answer. Your stack is different.

Check your whole stack

The Verdict

The supplement that activates the same cellular switch as exercise — and only the switch.

PQQ is a small ring-shaped molecule first discovered in soil bacteria in 1979. People take it because in cell-culture experiments it flips the same master switch that aerobic exercise flips — the one that tells your cells to build new mitochondria, the energy-producing machinery in every cell. The catch is that flipping the switch in a Petri dish is not the same as building useful mitochondria in a working human, and when researchers ran the obvious test (six weeks of PQQ during a real training program), the switch flipped and the performance did not.

The verdict: real signal at the biomarker level, null at the performance level, weak signal in cognitive aging dominated by small industry-funded trials, and zero human trials for longevity.
What most people get wrong: the "longevity vitamin" framing comes from a 2018 hypothesis paper, not a longevity trial. There is no longevity trial.
What to watch for: if you do the 12-week trial in cognitive aging, only the disodium salt has any human data. Skip "liposomal" and "enhanced bioavailability" forms — they cost four times more with zero head-to-head data.

Best For

Healthy adults aged 40+ willing to spend £15-60 per month on an unreplicated, industry-adjacent cognitive-aging trial with full disclosure that the evidence is small and lacks independent meta-analysis.

Skip If

You want ergogenic, longevity, cancer prevention, or neuroprotection benefit. You are pregnant, lactating, in active cancer treatment, or considering it for a child.

Want the full evidence? Keep scrolling

The Protocol

Dosing

Population	Dose	Timing	Form	Duration
Healthy adults 40+ (cognitive-aging trial)	20 mg/day	With a meal	PQQ disodium salt (BioPQQ™ / mnemoPQQ®)	12 weeks; stop if no perceived benefit
Untrained adults seeking aerobic / ergogenic	NOT EFFECTIVE — Hwang 2020 NULL on VO2peak, exercise duration, body composition despite biomarker elevation
MCI elderly	NOT VALIDATED — only trial used dihydrogen+PQQ combination that cannot isolate PQQ
Active cancer / chemotherapy	AVOID — PGC-1α implicated in tumour bioenergetics; oncology consult required
Pregnancy / lactation / children	AVOID — no human safety data

Forms Comparison

Disodium Salt

Plasma 16-54 nM at 3h

Only form with human RCT efficacy data. Branded BioPQQ™ or mnemoPQQ®.

£15-60 / month

Liposomal / Enhanced Bioavailability

No human PK data

Marketing PK claim with zero published human comparison or outcome trial.

£80-150+ / month

Free PQQ Acid (non-salt)

No human PK data

Lower aqueous solubility. Not used in any human trial.

Variable

Dietary PQQ (food)

Trace nanograms/serving

Parsley, green peppers, kiwi, fermented soy, green tea. Three orders of magnitude below trial doses.

Pennies

Absorption Tips

Take with a meal. Every published RCT doses with a meal. Avoid stacking with high-dose vitamin C, vitamin E, NAC, or polyphenol antioxidants around training — the additive antioxidant load inherits the antioxidants-exercise-blunting concern documented for the wider mitochondrial-cofactor mechanism family.

Safety & Interactions

Active cancer / chemotherapy — Mechanism caution

PGC-1α (the pathway PQQ activates) is implicated in tumour bioenergetics. No clinical trials in oncology populations. Oncology consult required before any use during active cancer treatment.

PQQ-GDH glucose meters — Informational only

Older mutQ-GDH glucose meter technology can give erroneously elevated glucose readings due to maltose interference (PMID 28500115). This is a meter-side issue, not a PQQ-side adverse event. Use a non-PQQ-GDH meter if you are concerned.

Drug-metabolism interactions — Data unavailable

No clinical pharmacology drug-drug interaction studies have been published in humans. No documented CYP450 interactions. The absence of data is not a safety claim.

Contraindicated Populations

Active cancer / chemotherapy — mechanism-based caution; oncology consult required
Pregnancy and lactation — no human safety data
Children — no human efficacy or safety data
Adults stacking high-dose multi-antioxidants around training — additive load inherits the antioxidants-exercise-blunting concern

Side Effects

None reported in published human RCTs at 20 mg/day for up to 12 weeks. Long-term safety beyond 12 weeks is underpowered. Tolerability documented to 100 mg/day in dose-escalation work.

Upper Limit

No formal Tolerable Upper Intake Level established by EFSA, NIH ODS, or IOM. No ISSN position stand. No EFSA-endorsed health claim at consumer doses.

Conviction: LOW

The PGC-1α biomarker elevation in human muscle is real. The translation to clinical outcomes ranges from null (ergogenic) to weak (cognitive aging) to absent (longevity, cancer prevention, neuroprotection). The trial gap is wide and unlikely to close in the supplement timeframe because no one is funding multi-year hard-outcome RCTs on PQQ.

What would change this

An independent (non-industry-funded), double-blind, placebo-controlled RCT of N≥120 healthy adults aged 50-70, allocated 1:1 to PQQ disodium salt 20 mg/day vs identical placebo for 24 weeks, with a pre-registered primary cognitive endpoint analysed via intent-to-treat with multiple-comparisons correction, showing a clinically meaningful between-group difference (≥0.3 SD) with consistent direction across secondary endpoints — would upgrade cognitive-aging conviction from LOW to MODERATE.

For longevity claims, the trial gap is essentially uncrossable in the supplement timeframe — a multi-year hard-outcome RCT (N≥1,000 over 5+ years on all-cause mortality or biological age) is not on any sponsor's roadmap.

Worth Your Money?

Estimated Weekly Cost

£4-15 per week at 20 mg/day disodium salt. £20-35 per week at premium "liposomal" or "enhanced bioavailability" forms with zero head-to-head data.

Worth It If

You are 40+, your cognitive-aging concern is high, and you are willing to spend £180-720 over a year on an unreplicated industry-adjacent trial with full disclosure of the evidence base.

Lower Priority If

Aerobic fitness is below average, sleep is poor, protein intake is low, or training is inconsistent. Aerobic exercise activates the same PGC-1α pathway as a clinical outcome rather than a biomarker — and per 1-MET higher cardiorespiratory fitness cuts all-cause mortality 11-17%. Better first dollars.

Skip — Save Your Money

Sources

Hwang PS et al. (2020). Effects of Pyrroloquinoline Quinone Supplementation on Aerobic Exercise Performance and Indices of Mitochondrial Biogenesis in Untrained Men. J Am Coll Nutr. PMID 31860387. RCT, N=23 untrained men, 20 mg/day × 6 weeks during supervised endurance training. NULL on aerobic performance and body composition; PGC-1α significantly elevated vs placebo. The single independent academic trial in the entire human PQQ literature.
Jager R et al. (2023). Pyrroloquinoline quinone disodium salt improves brain function in both younger and older adults. Food & Function. PMID 36807425. RCT, healthy adults aged 20-65, 20 mg/day × 12 weeks. Composite memory, verbal memory, cognitive flexibility, processing speed direction-favorable age-stratified.
Shiojima Y et al. (2022). Effect of Dietary Pyrroloquinoline Quinone Disodium Salt on Cognitive Function in Healthy Volunteers. J Am Nutr Assoc. PMID 34415830. mnemoPQQ® 21.5 mg/day × 12 weeks, N=58 elderly Japanese. Multi-domain cognitive improvement. Industry-adjacent (Cepham mnemoPQQ®).
Itoh Y et al. (2016). Effect of the Antioxidant Supplement Pyrroloquinoline Quinone Disodium Salt (BioPQQ) on Cognitive Functions. Adv Exp Med Biol. PMID 26782228. RCT, N=41 elderly, 20 mg/day × 12 weeks. Stroop interference reduced; Touch M only in lower-baseline subgroup. Industry-adjacent (Mitsubishi Gas Chemical BioPQQ™).
Sumi K et al. (2024). Six-week dihydrogen-pyrroloquinoline quinone supplementation on mitochondrial biomarkers, brain metabolism, and cognition in elderly individuals with MCI. J Nutr Health Aging. PMID 38908296. RCT, N=34 MCI elderly, Alpha Hope® dihydrogen+PQQ combination. BDNF within-arm p=0.01 but time×group interaction p=0.14 NS. Industry-funded combination intervention — cannot isolate PQQ.
Nakano M et al. (2016). Effects of Antioxidant Supplements (BioPQQ) on Cerebral Blood Flow and Oxygen Metabolism in the Prefrontal Cortex. Adv Exp Med Biol. PMID 27526146. RCT, N=20, 20 mg/day × 12 weeks. tNIRS prefrontal cortex; right PFC Hb increased. Industry-adjacent.
Nakano M et al. (2015). Effects of Pyrroloquinoline Quinone Disodium Salt Intake on the Serum Cholesterol Levels of Healthy Japanese Adults. J Nutr Sci Vitaminol. PMID 26226960. RCT, N=29, 20 mg/day × 12 weeks. TG: no change. LDL-C: marginal overall; significant in baseline LDL-C ≥140 subgroup (n≈11 post-hoc). Industry-adjacent.
Ames BN. (2018). Prolonging healthy aging: Longevity vitamins and proteins. PNAS. PMID 30322941. Hypothesis / perspective paper proposing PQQ as a candidate "longevity vitamin." NOT a human outcome trial.

Action ROI

Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.

Action ROI score

43/100 Low ROI Trust grade D

No - the mitochondrial pathway lights up but the performance never follows, and the cognition signal is small, industry-funded, and unreplicated.

Time

Low

Money

Medium

Effort

Low

Risk

Low

Why this score

The mitochondrial-energy goal is debunked at the outcome level: the single independent academic trial (Hwang 2020, PMID 31860387, N=23) confirmed muscle PGC-1a rose at 20 mg/day for 6 weeks, and in the same subjects VO2peak, exercise duration, and body composition did not move.
The cognition signal is real-but-weak and barely leverageable: it lives in four small trials (Jager 2023; Shiojima 2022, N=58; Itoh 2016, N=41), three of which rely on branded industry supply chains (BioPQQ or mnemoPQQ), with no meta-analysis, no replication, and no ISSN position stand.
Money is Medium for this thin payoff: about $19 to $75 a month for the disodium salt, while aerobic exercise drives the same PGC-1a pathway as an actual clinical outcome and has multi-million-subject mortality data behind it, for free.
Trust grade is D: zero human outcome RCTs for the 'longevity vitamin' claim (Ames 2018 is a hypothesis paper, not a trial), and the cholesterol claim rests on a single 11-subject post-hoc subgroup (Nakano 2015, N=29).
Risk is Low for a healthy buyer at 20 mg/day over 12 weeks (no adverse events reported), with the main caution being active cancer due to a mechanism-based concern - which is why this lands in Low rather than Poor ROI.

Why it didn’t score higher

The energy and mitochondrial-performance reason people buy it was directly tested and was null on every hard endpoint.
The longevity claim has zero human outcome RCTs, and that gap is unlikely to close because no sponsor is funding multi-year hard-outcome trials on PQQ.
The cognition evidence is small, industry-adjacent, and unreplicated, so even the one direction-favorable use is fragile.

Best for

Healthy adults aged 40+ seeking a subjective cognitive-aging trial, accepting that the evidence is small, unreplicated, and dominated by industry-adjacent trials
People who will time-limit it to a 12-week trial on the disodium salt and stop if they perceive no benefit

Lower ROI if

You are buying it for energy, endurance, or athletic performance - Hwang 2020 was null on all of these
You are buying it for longevity, biological age, or cancer prevention - there is zero human outcome RCT
You consider premium 'liposomal' or 'enhanced bioavailability' forms, which have no human data and cost up to 4x more
Your baseline cognition is fine and you are not specifically concerned about age-related decline

Minimum effective dose

20 mg/day of PQQ disodium salt (the BioPQQ or mnemoPQQ branded supply chain) with a meal, for 12 weeks, judged on subjective cognitive change in adults 40+. The dose-response above 20 mg/day is unmapped, and there is no evidence-based dose for the energy or longevity goal.

Track this

Subjective memory, focus, and processing speed over a 12-week trial, then stop if no perceived benefit
Honestly nothing objective tracks the longevity or energy claim - the biomarker (PGC-1a) rises without the outcome following
Whether the bottle is the studied disodium salt rather than a generic or 'liposomal' form with no efficacy data

The supplement that activates the same cellular switch as exercise — and only the switch.

Best For

Skip If

The Protocol

Dosing

Forms Comparison

Absorption Tips

Safety & Interactions

Active cancer / chemotherapy — Mechanism caution

PQQ-GDH glucose meters — Informational only

Drug-metabolism interactions — Data unavailable

Contraindicated Populations

Side Effects

Upper Limit

Worth Your Money?

Sources

Verdict Score

Action ROI

Get the complete dosing protocol

Related free research

There are 424 more inside